CY1123477T1 - Παραγωγα βενζοξαζινονης για την αγωγη δερματικων νοσων - Google Patents
Παραγωγα βενζοξαζινονης για την αγωγη δερματικων νοσωνInfo
- Publication number
- CY1123477T1 CY1123477T1 CY20201100988T CY201100988T CY1123477T1 CY 1123477 T1 CY1123477 T1 CY 1123477T1 CY 20201100988 T CY20201100988 T CY 20201100988T CY 201100988 T CY201100988 T CY 201100988T CY 1123477 T1 CY1123477 T1 CY 1123477T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- skin diseases
- specifically
- skin
- benzoxazinone derivatives
- Prior art date
Links
- 208000017520 skin disease Diseases 0.000 title abstract 2
- HQQTZCPKNZVLFF-UHFFFAOYSA-N 4h-1,2-benzoxazin-3-one Chemical class C1=CC=C2ONC(=O)CC2=C1 HQQTZCPKNZVLFF-UHFFFAOYSA-N 0.000 title 1
- SFDGJDBLYNJMFI-UHFFFAOYSA-N 3,1-benzoxazin-4-one Chemical class C1=CC=C2C(=O)OC=NC2=C1 SFDGJDBLYNJMFI-UHFFFAOYSA-N 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 101000605520 Homo sapiens Kallikrein-14 Proteins 0.000 abstract 1
- 101001091379 Homo sapiens Kallikrein-5 Proteins 0.000 abstract 1
- 101001091388 Homo sapiens Kallikrein-7 Proteins 0.000 abstract 1
- 102000001399 Kallikrein Human genes 0.000 abstract 1
- 108060005987 Kallikrein Proteins 0.000 abstract 1
- 102100038298 Kallikrein-14 Human genes 0.000 abstract 1
- 101710115806 Kallikrein-14 Proteins 0.000 abstract 1
- 102100034868 Kallikrein-5 Human genes 0.000 abstract 1
- 101710176223 Kallikrein-5 Proteins 0.000 abstract 1
- 102100034867 Kallikrein-7 Human genes 0.000 abstract 1
- 101710176222 Kallikrein-7 Proteins 0.000 abstract 1
- 208000011219 Netherton syndrome Diseases 0.000 abstract 1
- 102000035195 Peptidases Human genes 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 102000047743 human KLK14 Human genes 0.000 abstract 1
- 102000055383 human KLK7 Human genes 0.000 abstract 1
- 102000018483 human kallikrein 5 Human genes 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/539—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more oxygen atoms in the same ring, e.g. dioxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
- C07D265/22—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1430003 | 2014-01-23 | ||
| PCT/SE2015/050062 WO2015112081A1 (en) | 2014-01-23 | 2015-01-22 | Benzoxazinone derivatives for treatment of skin diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123477T1 true CY1123477T1 (el) | 2022-03-24 |
Family
ID=53681747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100988T CY1123477T1 (el) | 2014-01-23 | 2020-10-20 | Παραγωγα βενζοξαζινονης για την αγωγη δερματικων νοσων |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9695194B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3097085B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6448651B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106132941B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015209761B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2934025C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1123477T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3097085T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2820868T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20201500T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE051296T2 (cg-RX-API-DMAC7.html) |
| LT (1) | LT3097085T (cg-RX-API-DMAC7.html) |
| PL (1) | PL3097085T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3097085T (cg-RX-API-DMAC7.html) |
| RS (1) | RS60830B1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI3097085T1 (cg-RX-API-DMAC7.html) |
| SM (1) | SMT202000557T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015112081A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6448651B2 (ja) * | 2014-01-23 | 2019-01-09 | シクセラ ファーマ エービー | 皮膚病の処置のためのベンゾオキサジノン誘導体 |
| KR102579996B1 (ko) * | 2015-05-13 | 2023-09-18 | 니혼노야쿠가부시키가이샤 | 안트라닐산 에스테르 화합물 또는 이의 염류 및 해당 화합물을 함유하는 농원예용 살균제 및 이의 사용 방법 |
| US10821094B2 (en) * | 2016-01-13 | 2020-11-03 | Children's Hospital Medical Center | Compositions and methods for treating allergic inflammatory conditions |
| KR20250070121A (ko) * | 2017-06-16 | 2025-05-20 | 아지트라 인코포레이티드 | Lekti 발현 재조합 미생물을 사용하는 네테르톤 증후군의 치료를 위한 조성물 및 방법 |
| US20200040103A1 (en) | 2018-03-14 | 2020-02-06 | Genentech, Inc. | Anti-klk5 antibodies and methods of use |
| EP3781588B1 (en) | 2018-04-20 | 2024-10-30 | Children's Hospital Medical Center | Blood biomarker for eosinophilic gastrointestinal disorders |
| GB201809378D0 (en) | 2018-06-07 | 2018-07-25 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US12297501B2 (en) | 2019-02-25 | 2025-05-13 | Children's Hospital Medical Center | Methods for diagnosing and treating eosinophilic gastritis |
| JP2022549087A (ja) | 2019-09-18 | 2022-11-24 | ジェネンテック， インコーポレイテッド | 抗ｋｌｋ７抗体、抗ｋｌｋ５抗体、多重特異性抗ｋｌｋ５／ｋｌｋ７抗体および使用方法 |
| CN114615984B (zh) * | 2019-10-01 | 2025-02-07 | 分子皮肤治疗公司 | 作为klk5/7双重抑制剂的苯并噁嗪酮化合物 |
| GB202001447D0 (en) * | 2020-02-03 | 2020-03-18 | Ucb Biopharma Sprl | Antibodies |
| BR102020009679A2 (pt) | 2020-05-14 | 2021-11-23 | Fundação Universidade Federal Do Abc - Ufabc | Anticorpos recombinantes humanos para inibição da calicreína tecidual humana 7 (klk7) e uso em doenças relacionadas ao processo de descamação da pele |
| TW202304890A (zh) * | 2021-04-14 | 2023-02-01 | 美商百歐克斯製藥公司 | Klk5雙環雜芳香族抑制劑 |
| JP2024520154A (ja) | 2021-06-01 | 2024-05-21 | シクセラ・ファーマ・アーベー | ６－エトキシ－７－メトキシ－２－（２－メチルスルファニルフェニル）－３，１－ベンゾオキサジン－４－オンの水中油型乳剤 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB115399A (en) * | 1917-03-28 | 1918-04-29 | Reginald Guley Lewis | Improved Delivery mechanism for Coin-freed Apparatus and the like. |
| GB1153994A (en) * | 1965-07-21 | 1969-06-04 | Aspro Nicholas Ltd | Hydroxyphenyl Anthranilic Acid Derivatives Capable of Absorbing 'Ultra-Violet Light and Compositions containing them |
| WO1999048878A1 (en) * | 1998-03-24 | 1999-09-30 | Novo Nordisk A/S | Heterocyclic compounds regulating clotting |
| PL1631295T3 (pl) * | 2003-06-06 | 2010-09-30 | Arexis Ab | Zastosowanie skondensowanych związków heterocyklicznych jako inhibitorów SCCE do leczenia chorób skóry |
| TWI419884B (zh) | 2010-06-24 | 2013-12-21 | Univ Chang Gung | 苯并雜氧嗪酮衍生物，其製備方法以及包含有此等衍生物的藥學組成物 |
| JP6448651B2 (ja) * | 2014-01-23 | 2019-01-09 | シクセラ ファーマ エービー | 皮膚病の処置のためのベンゾオキサジノン誘導体 |
-
2015
- 2015-01-22 JP JP2016544672A patent/JP6448651B2/ja active Active
- 2015-01-22 ES ES15740572T patent/ES2820868T3/es active Active
- 2015-01-22 AU AU2015209761A patent/AU2015209761B2/en active Active
- 2015-01-22 HR HRP20201500TT patent/HRP20201500T1/hr unknown
- 2015-01-22 SI SI201531393T patent/SI3097085T1/sl unknown
- 2015-01-22 EP EP15740572.1A patent/EP3097085B1/en active Active
- 2015-01-22 WO PCT/SE2015/050062 patent/WO2015112081A1/en not_active Ceased
- 2015-01-22 PL PL15740572T patent/PL3097085T3/pl unknown
- 2015-01-22 CA CA2934025A patent/CA2934025C/en active Active
- 2015-01-22 CN CN201580005383.4A patent/CN106132941B/zh active Active
- 2015-01-22 LT LTEP15740572.1T patent/LT3097085T/lt unknown
- 2015-01-22 US US15/113,750 patent/US9695194B2/en active Active
- 2015-01-22 SM SM20200557T patent/SMT202000557T1/it unknown
- 2015-01-22 PT PT157405721T patent/PT3097085T/pt unknown
- 2015-01-22 HU HUE15740572A patent/HUE051296T2/hu unknown
- 2015-01-22 RS RS20201128A patent/RS60830B1/sr unknown
- 2015-01-22 DK DK15740572.1T patent/DK3097085T3/da active
-
2017
- 2017-06-05 US US15/614,462 patent/US10072024B2/en active Active
-
2020
- 2020-10-20 CY CY20201100988T patent/CY1123477T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6448651B2 (ja) | 2019-01-09 |
| CA2934025A1 (en) | 2015-07-30 |
| HUE051296T2 (hu) | 2021-03-01 |
| US10072024B2 (en) | 2018-09-11 |
| ES2820868T3 (es) | 2021-04-22 |
| CN106132941A (zh) | 2016-11-16 |
| JP2017503798A (ja) | 2017-02-02 |
| US20170267692A1 (en) | 2017-09-21 |
| EP3097085A4 (en) | 2017-08-09 |
| WO2015112081A1 (en) | 2015-07-30 |
| SMT202000557T1 (it) | 2020-11-10 |
| PL3097085T3 (pl) | 2021-01-11 |
| CN106132941B (zh) | 2018-04-06 |
| RS60830B1 (sr) | 2020-10-30 |
| SI3097085T1 (sl) | 2020-11-30 |
| EP3097085B1 (en) | 2020-07-29 |
| DK3097085T3 (da) | 2020-10-26 |
| CA2934025C (en) | 2022-06-07 |
| PT3097085T (pt) | 2020-10-08 |
| EP3097085A1 (en) | 2016-11-30 |
| LT3097085T (lt) | 2020-10-12 |
| US20170002021A1 (en) | 2017-01-05 |
| HRP20201500T1 (hr) | 2020-12-25 |
| AU2015209761A1 (en) | 2016-07-07 |
| US9695194B2 (en) | 2017-07-04 |
| AU2015209761B2 (en) | 2018-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123477T1 (el) | Παραγωγα βενζοξαζινονης για την αγωγη δερματικων νοσων | |
| CY1123810T1 (el) | Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
| CY1124407T1 (el) | Ενωσεις αναστολεα αυτοταξινης | |
| CY1125436T1 (el) | Αναστολεις dna-pk | |
| CY1124959T1 (el) | Αναστολεις λυσινης ειδικης απομεθυλασης-1 | |
| CY1124436T1 (el) | Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια | |
| CY1123475T1 (el) | Αναστολεις της ειδικης για λυσινη απομεθυλασης-1 | |
| CY1125127T1 (el) | Αναστολεις λυσινης ειδικης απομεθυλασης-1 | |
| CY1123663T1 (el) | Πυριμιδινονες ως αναστολεις τελεστη χια | |
| EA201591764A1 (ru) | Варианты тканевого ингибитора металлопротеиназ третьего типа (timp-3), композиции и способы | |
| CY1120969T1 (el) | Παραγωγα κινοξαλινης χρησιμα ως τροποποιητες fgfr κινασης | |
| CY1125205T1 (el) | Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων | |
| CY1120361T1 (el) | Αναστολεις 2,3-διοξυγενασης ινδολαμινης (ido) | |
| CY1120862T1 (el) | Παραγοντες επαγωγης αποπτωσης για τη θεραπευτικη αγωγη καρκινου και ανοσων και αυτοανοσων ασθενειων | |
| CY1123906T1 (el) | Αναστολεις απομεθυλασης ιστονης | |
| MX373103B (es) | Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1). | |
| CY1123707T1 (el) | Νεοι αναστολεις καλλικρεϊνης 7 | |
| BR112018005779A2 (pt) | repressores de htt e usos dos mesmos | |
| EA201692091A1 (ru) | Хиноксалиновые соединения и их применение | |
| EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
| EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
| CY1125150T1 (el) | Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου | |
| MX395231B (es) | Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos. | |
| BR112017013568A2 (pt) | compostos bicíclicos fundidos para o tratamento de doenças | |
| CY1124907T1 (el) | Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα |